European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).

Israel - English - Ministry of Health

truemed ltd, israel - emapalumab - concentrate for solution for infusion - emapalumab 5 mg / 1 ml - emapalumab - gamifant is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (hlh) with refractory, recurrent or progressive disease or intolerance with conventional hlh therapy.